Zobrazeno 1 - 10
of 767
pro vyhledávání: '"E. Slatopolsky"'
Publikováno v:
Blood Purification. Jul2003, Vol. 21 Issue 4/5, p318. 9p.
Publikováno v:
Clinical nephrology. 54(4)
Secondary hyperparathyroidism and its effects on bone and viscera are among the most important complications of end-stage renal disease. Despite its ubiquity, little is known about the treated natural history of the disorder.We assembled a cohort of
Publikováno v:
Clinical nephrology. 54(4)
Calcitriol is widely used in conjunction with phosphorus-binders containing calcium to treat secondary hyperparathyroidism in dialysis patients. Its efficacy in patients with severe hyperparathyroidism is diminished, in part, due to glandular hyperpl
Autor:
E, Slatopolsky, J, Finch, P, Clay, D, Martin, G, Sicard, G, Singer, P, Gao, T, Cantor, A, Dusso
Publikováno v:
Kidney international. 58(2)
In treating secondary hyperparathyroidism, the target level of serum intact parathyroid hormone (I-PTH) should be three to five times normal to prevent adynamic bone disease. In circulation, there is a non-(1-84) PTH-truncated fragment, likely 7-84,
Publikováno v:
Journal of cellular biochemistry. 73(1)
1Alpha,25(OH)2D3 is an important negative regulator of parathyroid hormone (PTH) gene transcription. In parathyroid cells, as in other target tissues, 1alpha,25(OH)2D3 is degraded by side chain oxidation by the inducible 24-hydroxylase. We have previ
Autor:
G M, Chertow, M, Dillon, S K, Burke, M, Steg, A J, Bleyer, B N, Garrett, D T, Domoto, B M, Wilkes, D G, Wombolt, E, Slatopolsky
Publikováno v:
Clinical nephrology. 51(1)
We have previously shown sevelamer hydrochloride (RenaGel) to be an effective and well-tolerated treatment for hyperphosphatemia in hemodialysis patients.We performed a randomized clinical trial to compare the efficacy of RenaGel alone and RenaGel wi
Publikováno v:
The Journal of clinical endocrinology and metabolism. 82(7)
The hypercalcemia of various granulomatoses is caused by endogenous 1,25-dihydroxyvitamin D [1,25-(OH)2D3] overproduction by disease-activated macrophages. The inability of 1,25(OH)2D3 to suppress its synthesis in macrophages contrasts with the tight
Autor:
E. Slatopolsky, A. J. Brown
Publikováno v:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 7
Publikováno v:
Vitamin D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7dec0455cb78ee7f7cf0e8496eebd788
https://doi.org/10.1515/9783110882513-107
https://doi.org/10.1515/9783110882513-107
Publikováno v:
Vitamin D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b70dc4aeaaeaeff561ead9719f39f10
https://doi.org/10.1515/9783110882513-071
https://doi.org/10.1515/9783110882513-071